<DOC>
	<DOCNO>NCT00312728</DOCNO>
	<brief_summary>This open-label , multicenter , single-arm , Phase II trial bevacizumab combine first- second-line therapy patient metastatic non-squamous non-small cell lung cancer ( NSCLC ) previously treat central nervous system ( CNS ) metastases . A total 115 patient enrol study .</brief_summary>
	<brief_title>A Study Bevacizumab Combination With First- Second-Line Therapy Subjects With Treated Brain Metastases Due Non-Squamous NSCLC ( PASSPORT )</brief_title>
	<detailed_description />
	<mesh_term>Lung Neoplasms</mesh_term>
	<mesh_term>Carcinoma , Non-Small-Cell Lung</mesh_term>
	<mesh_term>Neoplasm Metastasis</mesh_term>
	<mesh_term>Brain Neoplasms</mesh_term>
	<mesh_term>Bevacizumab</mesh_term>
	<criteria>Signed informed consent Histologically cytologically confirm NSCLC except squamous cell carcinoma Treated brain metastasis without evidence progression hemorrhage treatment , ascertain clinical examination brain imaging ( MRI CT ) screen period Appropriateness first secondline systemic therapy advance NSCLC Eastern Cooperative Oncology Group ( ECOG ) performance status 0 1 Age ≥ 18 year For woman childbearing potential sexually active male , use accept effective method contraception ( e.g. , hormonal barrier method , abstinence ) prior study entry duration study Brain biopsy/neurosurgical procedure perform within 3 month prior Day 1 Progressive neurologic symptom Active malignancy lung cancer Current , recent , planned participation experimental drug study Prior treatment investigational market agent act antiangiogenesis mechanism Gross hemoptysis within 3 month prior Day 1 Inadequately control hypertension Unstable angina New York Heart Association Grade II great congestive heart failure ( CHF ) Abdominal fistula , gastrointestinal perforation , intraabdominal abscess within 6 month prior Day 1 Myocardial infarction within 6 month prior Day 1 Stroke within 6 month prior Day 1 Active symptomatic peripheral vascular disease within 6 month prior Day 1 History significant vascular disease Evidence bleed diathesis coagulopathy Known hypersensitivity component bevacizumab Inadequate organ function Serious nonhealing wound , ulcer , bone fracture Urine protein/creatinine ( UPC ) ratio ≥ 1.0 Major surgical procedure , open biopsy , significant traumatic injury within 28 day prior Day 1 , anticipation need major surgical procedure course study Pregnancy lactation Known evidence disseminate intravascular coagulation ( DIC ) Active infection fever &gt; 38.5°C within 3 day prior Day 1 Any medical condition ( include mental illness substance abuse ) deem clinician likely interfere patient 's ability sign inform consent , cooperate participate study , interfere interpretation result</criteria>
	<gender>All</gender>
	<minimum_age>18 Years</minimum_age>
	<maximum_age>N/A</maximum_age>
	<verification_date>August 2011</verification_date>
	<keyword>Brain Cancer</keyword>
	<keyword>Brain Metastases</keyword>
	<keyword>Avastin</keyword>
	<keyword>NSCLC</keyword>
	<keyword>Lung Cancer</keyword>
	<keyword>PASSPORT</keyword>
</DOC>